PURE Bioscience Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000

Reuters

Dec 16, 2025

<a href="https://laohu8.com/S/PURE">PURE Bioscience</a> Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000

PURE Biosciences Inc. reported its financial results for the fiscal first quarter ended October 31, 2025. The company posted net product sales of USD 0.71 million for the period. Total revenue, including royalty revenue, reached USD 0.71 million. Cost of goods sold amounted to USD 0.26 million, resulting in a gross profit of USD 0.45 million. Selling, general and administrative expenses were USD 0.74 million, and research and development expenses totaled USD 0.09 million. Total operating costs and expenses were USD 0.83 million. The company reported a loss from operations of USD 0.38 million and a net loss of USD 0.46 million for the quarter. Basic and diluted net loss per share was USD 0.00, with 111,886,473 shares used in the calculation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PURE Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215068126) on December 15, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2591262103"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2591262103\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2591262103?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591262103","market":"nz","top_or_hot":-1,"title":"PURE Bioscience Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PURE\">PURE Bioscience</a> Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PURE Biosciences Inc. reported its financial results for the fiscal first quarter ended October 31, 2025. The company posted net product sales of USD 0.71 million for the period. Total revenue, including royalty revenue, reached USD 0.71 million. Cost of goods sold amounted to USD 0.26 million, resulting in a gross profit of USD 0.45 million. Selling, general and administrative expenses were USD 0.74 million, and research and development expenses totaled USD 0.09 million. Total operating costs and expenses were USD 0.83 million. The company reported a loss from operations of USD 0.38 million and a net loss of USD 0.46 million for the quarter. Basic and diluted net loss per share was USD 0.00, with 111,886,473 shares used in the calculation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PURE Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215068126) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PURE Bioscience Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPURE Bioscience Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PURE\">PURE Bioscience</a> Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PURE Biosciences Inc. reported its financial results for the fiscal first quarter ended October 31, 2025. The company posted net product sales of USD 0.71 million for the period. Total revenue, including royalty revenue, reached USD 0.71 million. Cost of goods sold amounted to USD 0.26 million, resulting in a gross profit of USD 0.45 million. Selling, general and administrative expenses were USD 0.74 million, and research and development expenses totaled USD 0.09 million. Total operating costs and expenses were USD 0.83 million. The company reported a loss from operations of USD 0.38 million and a net loss of USD 0.46 million for the quarter. Basic and diluted net loss per share was USD 0.00, with 111,886,473 shares used in the calculation.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PURE Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215068126) on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4018","symbol_name":"居家用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL9dHbFR:1","article_id":"2591262103","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591262103","pubTimestamp":1765832743,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PURE Biosciences Inc. reported its financial results for the fiscal first quarter ended October 31, 2025. The company posted net product sales of USD 0.71 million for the period. Total revenue, including royalty revenue, reached USD 0.71 million. Cost of goods sold amounted to USD 0.26 million, resulting in a gross profit of USD 0.45 million. Selling, general and administrative expenses were USD 0.74 million, and research and development expenses totaled USD 0.09 million. Total operating costs and expenses were USD 0.83 million. The company reported a loss from operations of USD 0.38 million and a net loss of USD 0.46 million for the quarter. Basic and diluted net loss per share was USD 0.00, with 111,886,473 shares used in the calculation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4018":"居家用品","PURE":"PURE Bioscience"},"translate_title":"PURE Bioscience第一季度净亏损收窄至464,000美元，收入增长27%至708,000美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PURE":0.9},"content_text":"PURE Bioscience Q1 net loss narrows to USD 464,000 as revenue rises 27% to USD 708,000\n    \n\n        PURE Biosciences Inc. reported its financial results for the fiscal first quarter ended October 31, 2025. The company posted net product sales of USD 0.71 million for the period. Total revenue, including royalty revenue, reached USD 0.71 million. Cost of goods sold amounted to USD 0.26 million, resulting in a gross profit of USD 0.45 million. Selling, general and administrative expenses were USD 0.74 million, and research and development expenses totaled USD 0.09 million. Total operating costs and expenses were USD 0.83 million. The company reported a loss from operations of USD 0.38 million and a net loss of USD 0.46 million for the quarter. Basic and diluted net loss per share was USD 0.00, with 111,886,473 shares used in the calculation.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PURE Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251215068126) on December 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}